Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › PSCA: prostate stem cell antigen and distinguishing androgen receptor negative prostate cancer from benign prostatic hyperplasia

PSCA: prostate stem cell antigen and distinguishing androgen receptor negative prostate cancer from benign prostatic hyperplasia

US Patent 8759006 · Granted Jun 24, 2014

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Selecting and isolating desirable t lymphocytes by change in mass responses2021
Positron emission tomography probe to monitor selected sugar metabolism in vivo2017
High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targe2016
N-cadherin: target for cancer diagnosis and therapy2016
Antibodies against cancer target block tumor growth, angiogenesis and metastatis2016
High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targe2015
Engineered anti-prostate stem cell antigen (PSCA) antibodies for cancer targetin2015
Fully human antibodies against N-cadherin2014
N-cadherin: target for cancer diagnosis and therapy2014
PSCA: prostate stem cell antigen and uses thereof2013
PSCA: prostate stem cell antigen and uses thereof2013
Humanized anti-prostate stem cell antigen monoclonal antibody2013